Mometasone / Olopatadine
Mometasone/olopatadine is a combination corticosteroid and antihistamine nasal spray used to treat seasonal allergic rhinitis (hay fever symptoms) in adults and children 12 and older.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Mometasone / Olopatadine: Patient Information Guide
A plain-language walkthrough of Mometasone / Olopatadine — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Mometasone/olopatadine is a combination nasal spray approved to treat seasonal allergic rhinitis. Here's what the evidence supports:
- Ryaltris nasal spray is indicated for the treatment of symptoms of seasonal allergic rhinitis (hay fever) in adults and children 12 years of age and older
- Ryaltris nasal spray has also established safety and effectiveness for seasonal allergic rhinitis symptoms in pediatric patients 6 to 11 years of age
⚙️How it works▾
Ryaltris pairs two mechanisms in one spray. Olopatadine is a histamine-1 (H1) receptor blocker — it prevents histamine (the chemical your body releases during an allergic reaction) from binding and triggering sneezing, itching, and a runny nose. Mometasone furoate is a potent corticosteroid that broadly reduces nasal inflammation by suppressing multiple immune cell types — including mast cells, eosinophils, and lymphocytes — and the chemical messengers (such as histamine, leukotrienes, and cytokines) that drive swelling and irritation. The combination addresses both the immediate allergy response and the underlying inflammatory process.
💊How it's taken▾
Ryaltris comes as a metered nasal spray used twice daily, with one dose in the morning and one in the evening. Adults and patients 12 and older use 2 sprays in each nostril per dose; children 6 to 11 years use 1 spray in each nostril per dose. The bottle should be shaken before every use, primed before first use, and re-primed if not used for 14 or more days. Follow your prescriber's instructions exactly — do not use more than the recommended amount.
🤒Side effects — in detail▾
Most people tolerate Ryaltris well. The most commonly reported side effects include:
- Unusual or altered taste in the mouth (dysgeusia)
- Nosebleeds (epistaxis)
- Nasal discomfort or irritation
- Headache
- Drowsiness
More serious reactions — including nasal ulcers, a hole in the nasal septum, yeast infection in the nose or throat, vision changes, allergic reactions (wheezing, rash), or signs of adrenal suppression — require prompt medical attention. Contact your doctor right away if any of these occur.
⚠️Warnings & precautions▾
- Drowsiness and impaired alertness: Ryaltris can cause drowsiness. Avoid driving or operating heavy machinery until you know how it affects you. Do not combine with alcohol or other sedating medications.
- Nasal injury and infection: Nasal ulcers, septal perforations (a hole in the nasal divider), impaired wound healing, and localized yeast infections (Candida) have been reported. Don't use Ryaltris if you've had recent nasal surgery or injury until healing is complete.
- Immune suppression and infection risk: Corticosteroids suppress the immune system. Chickenpox and measles can be severe or fatal in people using corticosteroids. Avoid exposure if you haven't been vaccinated or had these illnesses. Use with caution if you have tuberculosis, fungal, bacterial, viral, or parasitic infections.
- Eye problems: Nasal corticosteroids can increase the risk of glaucoma (increased eye pressure) and cataracts. Tell your doctor about any vision changes.
- Adrenal suppression: Using more than the recommended dose, or long-term use in susceptible individuals, can suppress the adrenal glands' ability to make cortisol naturally.
- Slowed growth in children: Nasal corticosteroids may reduce growth velocity in children. Pediatric patients should have their height monitored regularly throughout treatment.
🔀What it interacts with▾
Ryaltris has a few important interactions to be aware of:
- Alcohol: Increases drowsiness and impairs alertness — avoid combining.
- CNS depressants (sleep aids, sedatives, anti-anxiety drugs, certain antihistamines): Amplify drowsiness and slow mental performance — avoid concurrent use.
- Strong CYP3A4 inhibitors (certain antifungals like ketoconazole, some HIV protease inhibitors, and others): Can block the enzyme that breaks down mometasone, raising its blood levels and the risk of steroid-related side effects — use with caution and tell your prescriber all medications you take.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not use Ryaltris if you have a known allergy to any of its ingredients, including mometasone furoate — allergic reactions including wheezing have been reported.
- Tell your doctor if you have glaucoma, cataracts, or a history of increased eye pressure.
- Tell your doctor if you have any active infection — especially tuberculosis, untreated fungal or bacterial infections, viral or parasitic infections, or ocular herpes simplex.
- Tell your doctor if you have recently had nasal surgery, nasal ulcers, or nasal trauma — wait until fully healed before using.
- Pregnancy: There are no adequate human safety data for Ryaltris in pregnancy. Animal studies showed fetal harm at high doses. Discuss the risks and benefits with your doctor.
- Breastfeeding: It is not known whether olopatadine or mometasone passes into human breast milk in meaningful amounts after nasal use. Talk to your doctor about whether to continue breastfeeding.
- Children under 6: Safety and effectiveness of Ryaltris have not been established in children younger than 6 years.
- Liver impairment: Mometasone levels may increase with worsening liver disease — inform your prescriber if you have liver problems.
- Older adults: Clinical studies included limited numbers of patients 65 and older; it is not known if they respond differently from younger adults.
🚑If you take too much▾
Taking too much olopatadine may cause drowsiness in adults; in children it may first cause agitation and restlessness followed by drowsiness. Chronic overuse of mometasone furoate can lead to hypercorticism (signs of too much cortisol, such as weight gain, easy bruising, or fatigue). If overdose is suspected, supportive care is recommended — contact a poison control center or seek medical attention promptly.
📡Pharmacodynamics — effects in the body▾
In a 12-month study of olopatadine alone (as a component of the combination), no effect on heart rhythm (QT prolongation) was observed. For the mometasone furoate component, studies comparing nasal doses to placebo showed no significant suppression of the adrenal glands' cortisol output at the recommended dose — unlike oral prednisone, which did significantly reduce cortisol levels. This suggests that Ryaltris used at the recommended dose is unlikely to meaningfully suppress the body's natural steroid production.
🔬Pharmacokinetics — how your body processes it▾
After nasal dosing with Ryaltris, both olopatadine and mometasone furoate reach peak blood levels within about 1 hour. Olopatadine has an elimination half-life of about 9 hours (meaning the body clears half of it roughly every 9 hours) and is mainly removed through urine largely unchanged. Mometasone furoate has a longer half-life of about 18 hours; it is extensively broken down (metabolized) and cleared mostly through bile, with very little entering the bloodstream from the nose — meaning systemic exposure from the nasal spray is very low.
📦How to store it▾
Store RYALTRIS upright with the purple dust cap on at room temperature (see USP Controlled Room Temperature, between 20°C and 25°C, or between 68°F and 77°F, with excursions permitted between 15°C to 30°C or between 59°F to 86°F). store in a freezer or refrigerator.
📄 Written from Mometasone / Olopatadine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Mometasone / Olopatadine — the kind of thing our pharmacy team would talk through with you at the counter.
What is Ryaltris actually for — is it just a regular allergy spray? ▾
Will Ryaltris make me drowsy? ▾
How do I use the nasal spray correctly? ▾
Are there any long-term risks I should know about since it contains a steroid? ▾
Can I use Ryaltris if I'm pregnant or breastfeeding? ▾
My nose feels irritated and I had a small nosebleed — should I stop using it? ▾
Is Mometasone / Olopatadine available over the counter? ▾
When was Mometasone / Olopatadine first available? ▾
Who makes Mometasone / Olopatadine? ▾
💬 Answers drafted from Mometasone / Olopatadine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Mometasone / Olopatadine comes
Mometasone / Olopatadine is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Nasal spray
How this form is used
- Ryaltris is indicated to treat symptoms of seasonal allergic rhinitis in adults and children 12 years of age and older
- Ryaltris safety and effectiveness for seasonal allergic rhinitis symptoms have also been established in children 6 to 11 years of age
- Ryaltris is for intranasal use only — spray into the nostrils, never in the eyes or mouth
- Ryaltris should be shaken well before each use
- Ryaltris must be primed before first use (6 sprays) and re-primed with 2 sprays if not used for 14 or more days
- Ryaltris is given twice daily; adults and patients 12 and older use 2 sprays per nostril, while children 6–11 use 1 spray per nostril
📊 Mometasone / Olopatadine across the U.S. market
How Mometasone / Olopatadine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Mometasone / Olopatadine is used
A general measure of how commonly Mometasone / Olopatadine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Mometasone / Olopatadine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Mometasone / Olopatadine prescribed? Of the 1,596 medications we measure, Mometasone / Olopatadine ranks #1,021 by Medicaid prescriptions — more than 36% of them.
Utilization by Mometasone / Olopatadine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2591806
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Mometasone / Olopatadine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 4 listed Mometasone / Olopatadine NDCs with Medicaid activity.
🔍 Compare Mometasone / Olopatadine products
A representative set of FDA-listed product records for Mometasone / Olopatadine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Nasal spray | ||||
| MOMETASONE FUROATE MONOHYDRATE 25 mcg/1; OLOPATADINE HYDROCHLORIDE 665 mcg | Nasal | Glenmark Pharmaceuticals Inc., USA | NDA | View NDC → |
| OLOPATADINE HYDROCHLORIDE 665 mcg/1; MOMETASONE FUROATE MONOHYDRATE 25 mcg | Nasal | Glenmark Pharmaceuticals Inc., USA | NDA | View NDC → |
| OLOPATADINE HYDROCHLORIDE 665 mcg/1; MOMETASONE FUROATE MONOHYDRATE 25 mcg | Nasal | Hikma Specialty Usa Inc. | NDA | View NDC → |
| 25; 665 mcg/1; mcg | Nasal | Hikma Specialty Usa Inc. × 2 listings | NDA | View NDC → |
Showing 5 of 5 products — FDA National Drug Code Directory. See every product, package size and price: browse all 5 Mometasone / Olopatadine NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Mometasone / Olopatadine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Mometasone / Olopatadine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Mometasone / Olopatadine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one exact multiple-ingredient concept (MIN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). A product with a different ingredient combination belongs on a different page.
RxCUI 2591802 1 dose form · 1 strength
-
Dose form (SCDF) Metered Dose Nasal Spray RxCUI 2591805In current FDA listingsClinical drug / strength (SCD) mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUATRxCUI 2591806
Look up RxCUI 2591802 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Mometasone / Olopatadine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Mometasone / Olopatadine belongs to the Corticosteroid class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 2 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Glenmark Pharmaceuticals Inc., USA is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.